RNAC

Cartesian Therapeutics, Inc.
CAPPED RATING

Cartesian Therapeutics, Inc. (RNAC) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D).

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
D+
Factor Score 1.8 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
D+
Factor Score 1.6 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.7
EV / EBITDA -1.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -30.8%
Price Return 12M -16.2%
Catalyst Signal 0.00
Market Cap $193.7M
TTM Revenue $1.0M
Price / Sales 189.0
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 D+ (1.8) D (1.3) D+ (1.6) C- (2.1) C+ (2.6) C- (1.9)
2026-11-07 D+ (1.7) D- (0.8) D- (0.7) C (2.3) C+ (2.7) D+ (1.6)
2026-10-31 C- (2.1) D- (1.1) D+ (1.8) C+ (2.7) C+ (2.7) C- (2.1)
2026-10-24 C (2.2) D- (1.1) D+ (1.8) C (2.4) C+ (2.6) C- (2.0)
2026-10-17 C (2.2) D- (1.1) D+ (1.8) C (2.4) C+ (2.6) C- (2.0)
Page 1 of 4